By Sabela Ojea
Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes.
The biopharmaceutical companies on Wednesday said that they expect the product to be available for order in the U.S. early in February. Incyte has exclusive commercialization rights for Niktimvo outside the U.S.
Niktimvo was approved by the FDA on Aug. 14 for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kilograms. Graft-versus-host disease is a severe complication that can occur following hematopoietic stem cell transplantation.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 15, 2025 18:12 ET (23:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.